WESTMINSTER, Colo., June 25, 2012 /PRNewswire/ -- GeneThera Inc. (OTCQB: GTHR) is pleased to announce that Applied Genetics, GeneThera's majority owned subsidiary, has initiated commercial operation of its molecular diagnostic laboratory based in Monterrey, Mexico. Applied Genetics molecular diagnostic laboratory is the first molecular laboratory in Mexico, to date, which is capable to detect Johne's disease at the molecular level in milk, blood, and feces from dairy cows, goats and sheep infected with the disease using state-of-the-art molecular technology. Applied Genetics utilizes GeneThera proprietary Johne's disease HerdCheck™ Field Collection System (FCS) Molecular Assay. Dr. Tony Milici, interim president of Applied Genetics and CEO of GeneThera, stated; "The starting of Applied Genetics commercial operation is a great success for GeneThera. I think it is pretty remarkable that we were able to accomplish our goal in less than 18 months. This achievement was made possible thanks to the commitment and dedication of the Company's management and the outstanding support of our loyal investors and collaborators. I have to thank deeply all the people who believed in the Company and its ability to achieve its goals; I am grateful."
Nutrition Avanzada, GeneThera's exclusive buyer and distributor of the proprietary Johne's disease molecular system in Mexico, has entered into an agreement with a large veterinary laboratory in Northern Mexico. This agreement will provide access to about 20,000 animals initially. These animals will be tested for the presence of mycobacterium paratuberculosis in milk, blood and feces. Positive animals will be tested every 3 months to monitor progress of the disease. The cost of the test will range from US $30.00 – $32.00. In addition, Nutrition Avanzada is in the final negotiation stages with two of the largest dairy companies in Mexico.
As previously announced Nutricion Avanzada will purchase the Johne's disease Field Collection System kit from Applied Genetics and resell it directly to third parties. Samples will be then shipped to Applied Genetics laboratory for processing. The commercial operation will be implemented in Three (3) Phases: during the current initial Phase (Phase I), Applied Genetics target is to process a maximum of 100 samples/daily. Phase II, to be initiated in late fall of 2012, will increase Applied Genetics sample process throughput to 1500 samples/daily. Phase II will be implemented in the early part of 2013, which will further increase sample throughput to over 2000 samples daily.
Johne's disease is a global devastating and incurable disease of dairy cows, sheep and goats caused by a bacterium called Mycobacterium Paratuberculosis sub. Avium, (MAP). Dairy products, contaminated with MAP, are the vehicles by which the infection spreads in the human intestine triggering the onset of Crohn's disease. Applied Genetics employs the use of GeneThera HerdCheck™ to test and control the spread of Johne's disease in Mexico. HerdCheck™ is a proprietary molecular diagnostic system based on the use of high throughput robotics and Real time PCR.
About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company located in Westminster, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression system, GES™ and Johne's disease management system, HERDCHECK™ designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES™ and HERDCHECK™ systems are designed for a host of individual diseases, the current priority being Johne's disease. For more information, contact Dr. Tony Milici at 720-439-3011. http://www.genethera.net
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
|SOURCE GeneThera, Inc.|
Copyright©2012 PR Newswire.
All rights reserved